Co-infection of SENV-D among chronic hepatitis C patients treated with combination therapy with high-dose interferon-alfa and ribavirin

Table 1 Comparison of clinical characteristics between individuals with and without SENV-D viremia in 164 CHC patients

	SENV-D viremia		P
	Positive (n = 61)	Negative (n = 103)
Sex (male) (%)	36 (59.0)	61 (59.2)	NS
Age (yr)	50.7 ± 10.6	46.6 ± 11.6	0.026
Serum ALT (IU/L)	144.0 ± 164.3	125.8 ± 164.2 )	NS
Normal ( ≤ 34 IU/L) (%)	8 (33.3)	16 (66.7)	NS
Abnormal (> 34 IU/L) (%)	53 (37.9)	87 (62.1)
HCV RNA levels (log IU/mL)	5.72 ± 0.70	5.85 ± 0.63	NS
HCV genotype 1b (%)	26 (42.6)	54 (52.4)	NS
Histology (HAI scores)	46	82
Peri-portal necrosis	1.11 ± 1.34	1.11 ± 1.35	NS
Intralobular necrosis	0.70 ± 1.00	0.41 ± 0.78	NS
Portal inflammation	1.80 ± 1.31	1.98 ± 1.21	NS
Total score (grading)	3.54 ± 2.65	3.49 ± 2.52	NS
Fibrosis	1.39 ± 1.50	1.16 ± 1.28	NS

Results are expressed as mean±SD. HAI: histological activity index, NS: no significance.